新靶点与新潜力：慢性肾脏病炎症治疗的进展
Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.
作者信息
Kovesdy Csaba P, Kalantar-Zadeh Kamyar
机构信息
Salem VAMC (111D), 1970 Roanoke Blvd., Salem, VA 24153, USA.
出版信息
Expert Opin Investig Drugs. 2008 Apr;17(4):451-67. doi: 10.1517/13543784.17.4.451.
BACKGROUND
Patients with chronic kidney disease (CKD) of all stages experience extremely high mortality, with cardiovascular causes accounting for about half of all their deaths. Traditional risk factors such as hypertension, hypercholesterolemia and diabetes mellitus cannot explain the excessively high cardiovascular mortality in CKD. Chronic inflammation is one of the novel risk factors that appear to contribute to the increased mortality seen in patients with CKD. Therapeutic interventions targeting chronic inflammation in CKD may lead to improved outcomes.
OBJECTIVES
To describe the role of inflammation in CKD and to review anti-inflammatory pharmacologic therapies that could have a role in its therapy.
METHODS
A review of the literature was carried out and expert opinion expressed.
RESULTS/CONCLUSION: Inflammation is a common and significant problem in CKD. There are currently no approved pharmacologic anti-inflammatory therapies in CKD but several agents are being studied in early clinical trials, while others could become viable alternatives in the future.
背景
各阶段慢性肾脏病（CKD）患者的死亡率极高，心血管病因约占其所有死亡病例的一半。高血压、高胆固醇血症和糖尿病等传统危险因素无法解释CKD患者过高的心血管死亡率。慢性炎症是导致CKD患者死亡率增加的新危险因素之一。针对CKD慢性炎症的治疗干预可能会改善预后。
目的
描述炎症在CKD中的作用，并综述可能在其治疗中发挥作用的抗炎药物疗法。
方法
进行文献综述并发表专家意见。
结果/结论：炎症是CKD中常见且重要的问题。目前CKD尚无获批的抗炎药物疗法，但有几种药物正在早期临床试验中进行研究，其他药物未来可能成为可行的替代方案。
Zotero 插件